Scores of PASDAS components at Wk 16
| Core components, | Secukinumab/PBO (s.c.), | LDA | HDA |
|---|---|---|---|
| Mean ± SD | mg | 300mg: n=37; | 300mg: n=12; |
| 150mg: n=34; | 150mg: n=23: | ||
| PBO: n=14 | PBO: N=34 | ||
| Physician/Pt Global VAS | 300 | 7.3±7.2/14.6±10.3 | 43.2±10.2/65.7±21.6 |
| 150 | 8.3±8.7/13.2±10.3 | 55.7±16.2/67.8±14.9 | |
| PBO | 11.4±9.8/16.7±13.4 | 56.7±12.8/64.8±15.6 | |
| SF-36 PCS | 300 | 51.5±5.8 | 34.9±6.0 |
| 150 | 51.8±5.5 | 34.2±6.5 | |
| PBO | 49.4±6.6 | 33.5±8.2 | |
| SJC 66/TJC 68 | 300 | 2.2±3.0/2.3±3.4 | 12.3±10.0/27.9±16.1 |
| 150 | 1.9±3.6/2.6±5.0 | 15.9±11.1/32.3±21.7 | |
| PBO | 1.7±2.0/3.4±4.7 | 10.1±6.1/25.4±14.0 | |
| Leeds Enthesitis Score | 300 | 0.3±0.8 | 3.0±2.5 |
| 150 | 0.1±0.3 | 3.0±2.5 | |
| PBO | 0.2±0.6 | 2.4±1.8 | |
| Tender Dactylitis count | 300 | 0.03±0.2 | 0.9±2.6 |
| 150 | 0 | 1.4±3.1 | |
| PBO | 0.1±0.5 | 1.3±2.4 | |
| CRP (mg/L) | 300 | 3.3±3.5 | 5.0±4.5 |
| 150 | 3.3±3.5 | 8.1±11.6 | |
| PBO | 5.8±15.2 | 14.7±19.5 | |